← Search & browse all drugs
NERVOUS SYSTEM › PSYCHOLEPTICS › HYPNOTICS AND SEDATIVES › Other hypnotics and sedatives
apronal
N05CM12
Forms & Strengths
- Tablets: 300 mg (historically available in combination products)
- Powder for compounding
Adult Dosing
- Insomnia/Sedation: 300 mg to 600 mg orally at bedtime
- Max daily dose: 1000 mg
Pediatric Dosing
- Safety and efficacy not established in pediatric patients; not recommended
Indications
- Short-term treatment of insomnia
- Mild daytime sedation (historical use)
Mechanism of Action
- Ureide derivative acting as a central nervous system depressant
- Enhances inhibitory GABAergic neurotransmission in the cerebral cortex, leading to sedative and hypnotic effects
Contraindications
- Hypersensitivity to apronal or related ureides/barbiturates
- Acute intermittent porphyria
- Severe hepatic or renal impairment
- History of drug-induced thrombocytopenia
Adverse Reactions
- Drowsiness and somnolence
- Dizziness and ataxia
- Thrombocytopenic purpura (immune-mediated)
- Allergic skin rashes and dermatitis
- Respiratory depression in high doses
- Dependence and withdrawal symptoms with chronic use
Drug Interactions
- CNS depressants (alcohol, opioids, benzodiazepines): additive sedative and respiratory depressive effects
- Hepatic enzyme inducers: potential alteration of clearance
- Myelotoxic drugs: potential additive risk of hematological adverse effects
Curated Content: Needs Vetting Before Put to Clinical Use